Hormone Replacement Therapy Market is Estimated to Grow at a CAGR of 6.1% from 2022 to 2028

As stated in our extensive report; the Global Hormone Replacement Therapy Market accounted for USD 20.1 Billion in 2021.

Factors such as the rising prevalence of target diseases and the availability of long-acting GH medicines are fueling the growth of the HRT industry. According to the American Thyroid Association’s best guesses, twelve percent of U.S. citizens will be affected by thyroid illness at some point in their lives. In addition, it was estimated that 20 million Americans have thyroid problems. Furthermore, multiple studies found that HRT patients were less likely to get COVID-19 and live shorter overall.

5,451 COVID cases associated with HRT (oestrogen therapy treatment) experienced a 78% decrease in infection and mortality rate, according to a study conducted by the Oxford-Royal College of General Practitioners Research and Surveillance Centre, which examined 1.8 million medical records of women from 465 general practitioners. Conversely, males typically have more serious infections, more significant hospitalization and fatality rates, and more severe infections overall.


The Hormone Replacement Therapy Market is segmented based on Product, Route of Administration, Indication, Distribution Channel, and Region. On the basis of Product, the market is segmented into Oestrogen Hormone Replacement Therapy, Human Growth Hormone Replacement Therapy, Thyroid Hormone Replacement Therapy, and Testosterone Hormone Replacement Therapy. On the basis of the route of Administration, the market is segmented into Oral, Parenteral, Transdermal, and Others. On the basis of the indication, the market is segmented into Menopause, Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, and Others. On the basis of distribution channels, the market is segmented into Hospitals Pharmacies, Retail Pharmacies & Stores and Online Pharmacies. Region-wise, the Global Hormone Replacement Therapy Market has been segmented into North America, Europe, North America, Latin America, and Middle East & Africa.

Market Dynamics

These treatments are essential for a variety of patients, including those with growth hormone shortages, menopausal issues in women, and hypogonadism in the elderly. The medication is offered in many different formats, including skin and buccal patches, injections, tablets, and others. Due to the increased use of these goods around the world, producers are concentrating on creating cutting-edge medication delivery systems, like transdermal oestrogen patches and vaginal oestrogen pills. In keeping with the safety concerns, they are also concentrating on the introduction of low-dose oestrogen therapy rather than high-dose oestrogen therapy. The introduction of gel-based formulations for oestrogen patches and other products is another development in the worldwide market that the major companies in the industry have implemented.

The introduction of the estradiol gel formulation, which is typically prescribed for low doses and individuals who are resistant to oral oestrogen therapy, also contributes to the market’s growth. The FDA has approved estradiol gels for the treatment of menopausal symptoms since they are simple to use and cause the fewest skin problems. One such medication is Estrasorb, which is applied to the skin of the thigh and contains a liposomal formulation. In addition, a pump that typically delivers 1.25g doses of hydroalcoholic gel, which contains 0.75mg of 17beta-estradiol, is also available in the United States. Without leaving any residue, this gel absorbs into the skin and dries in 2 to 5 minutes. The market is expected to increase substantially during the projected period due to the launch of such cutting-edge medication delivery methods and sophisticated hormone therapies.

During the forecast period, the Hormone Replacement Therapy Market in North America is anticipated to develop at the quickest rate. The greatest market share in the region is a result of several product releases, manufacturer collaboration agreements, and helpful reimbursement regulations, among other things. For instance, the U.S. FDA authorized Novo Nordisk A/Sogroya S’s (somapacitan-beco), a medication for HGH replacement therapy, in August 2020. Adults with growth hormone insufficiency are prescribed this medication once per week via a subcutaneous method.


Increased demand for natural Hormone Replacement Therapys, will have a favorable impact on the overall Hormone Replacement Therapy Market.

Some of the key players in the Global Hormone Replacement Therapy Market include- Bayer AG (Germany), Pfizer Inc. (US), Merck & Co. Inc. (US), Viatris Inc. (US), Novo Nordisk A/S (Denmark), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), Noven Pharmaceuticals Inc. (US), ASCEND Therapeutics US LLC. (US), AbbVie Inc. (US) and others.